(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Phathom Pharmaceuticals's revenue in 2026 is $239,663,000.On average, 13 Wall Street analysts forecast PHAT's revenue for 2026 to be $26,751,511,846, with the lowest PHAT revenue forecast at $24,779,956,084, and the highest PHAT revenue forecast at $28,456,903,535. On average, 13 Wall Street analysts forecast PHAT's revenue for 2027 to be $42,167,184,819, with the lowest PHAT revenue forecast at $35,677,311,894, and the highest PHAT revenue forecast at $48,071,334,983.
In 2028, PHAT is forecast to generate $57,950,957,043 in revenue, with the lowest revenue forecast at $47,722,651,957 and the highest revenue forecast at $67,031,277,875.